Clinical trials: Hyperlipoproteinemia (a)
Homozygous Familial Hypercholesterolemia
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous…
- Trial name
- NCT07037771
- Testing
- zodasiran Injection
- Where
- 43 sites in United States, Australia and 16 more
- Volunteers
- 70 people
- Sponsor
- Arrowhead Pharmaceuticals
Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
This is a multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluating the efficacy and safety of IBI306 monotherapy in Chinese Paricipants with non-familial hypercholesterolemia and mixed…
- Trial name
- NCT07473960
- Testing
- IBI306
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Primary Dyslipidemia, Mixed Dyslipidemia
Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.
- Trial name
- PREVAIL-US (NCT01256476)
- Testing
- pitavastatin, pravastatin
- Where
- 44 sites in United States
- Volunteers
- 328 people
- Sponsor
- Kowa Research Institute, Inc.
Hypertriglyceridemia, Familial Chylomicronemia
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple doses of ARO-APOC3 in healthy adult volunteers and in patients with severe hypertriglyceridemia and…
- Trial name
- NCT03783377
- Testing
- ARO-APOC3, sterile normal saline (0.9% NaCl)
- Where
- 10 sites in Australia, Canada and 1 more
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Disease, Hypertension
A Pilot Study to Improve Patient-Doctor Communication
The purpose of this controlled pilot study is to determine whether an intervention aimed at patients will improve partnering, shared decision-making and open communication.
- Conditions
- Chronic Disease, Hypertension, Hyperlipidemia, Diabetes Mellitus
- Trial name
- NCT01606930
- Testing
- Patient Primer Tool
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Walter Reed National Military Medical Center
Hyperlipidemia
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
The study is being conducted to evaluate the efficacy and safety of HRS-7249 for patients with hyperlipidemia, and to explore the reasonable dosage of HRS-7249 for patients with hyperlipidemia.
- Trial name
- NCT07100418
- Testing
- HRS-7249 Injection, Sodium Chloride Injection
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet
A phase I, Open-label, Randomized, Single-dose, 2 x 2 Crossover Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet and Coadministration of Fimasartan and Atorvastatin as Individual Tablets in…
- Trial name
- NCT02566187
- Testing
- Fimasartan/Atorvastatin Combination Tablet, Fimasartan, Atorvastatin
- Where
- South Korea
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypercholesterolemia, Dyslipidemias
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W [≤31 days]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic…
- Conditions
- Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
- Trial name
- NCT06568471
- Testing
- Lerodalcibep
- Where
- 18 sites in China
- Volunteers
- 210 people
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD)
PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis
PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease.
- Trial name
- NCT07856264
- Volunteers
- 100 people
- Sponsor
- Fundación Santa Fe de Bogota
Hypercholesteremia, Hyperlipidemia
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
This is a 12-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the efficacy of MK0524 to improve the tolerability of extended-release niacin.
- Trial name
- NCT00376584
- Testing
- MK-0524A, ER Niacin
- Volunteers
- 825 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Familial
Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
The purpose of this protocol is to identify and screen potential candidates for future enrollment in a gene therapy clinical trial for HoFH.
- Trial name
- NCT03018678
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Pennsylvania
Hyperlipemia
The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy, as well as immunogenicity of JS002 treated repeatedly in patients…
- Trial name
- NCT04781114
- Testing
- JS002
- Where
- 57 sites in China
- Volunteers
- 806 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of triglyceride (TG) levels in participants with FCS.
- Conditions
- Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
- Trial name
- NCT03360747
- Testing
- AKCEA-ANGPTL3-LRx
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Akcea Therapeutics
Implant Stability
Stability Of Dental Implants Placed In Healed Bony Sites Of Hyperlipidemic Patients: A Case Series
Statement of the problem: Osseo-integration of dental implants depends mainly on bone regeneration around dental implant. Hyperlipidemia has significant adverse effects on bone health, leading to lower bone mineral density and to…
- Trial name
- NCT04718246
- Testing
- Dental Implants Placed In hyperlipidemia patients
- Where
- Egypt
- Volunteers
- 12 people
- Sponsor
- Cairo University
Hyperlipidemias
Daily Inclusion of Eggs in a Heart-Healthful Dietary Pattern in Hyperlipidemic Adults
This randomized, cross-over design, controlled trial will assess the effects of 8 weeks of daily inclusion of 2 whole eggs in the Dietary Approaches to Stop Hypertension (DASH) eating plan, compared with their exclusion, on…
- Trial name
- NCT05807334
- Testing
- DASH eating plan with eggs, DASH eating plan without eggs
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Griffin Hospital
Hyperlipidemia
Evaluation of the Hypolipidemic Effect of Bergavit by a Human Trial.
Bergavit is a product contains bergamot. Bergamot is an endemic plant of the Calabrian region in southern Italy with a unique profile of flavonoids and flavonoid glycosides present in its juice and albedo, its flavonoids was able…
- Trial name
- NCT06692777
- Testing
- Bergavit
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chung Shan Medical University
Hyperlipemia
A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody.
- Trial name
- NCT04469673
- Testing
- Biological：JS002
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Homozygous Familial Hypercholesterolemia
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.
- Trial name
- ORION-2 (NCT02963311)
- Testing
- ALN-PCSSC, Standard of Care
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 9 people
- Sponsor
- The Medicines Company
Familial Hyperlipidemia
School-based Education and Screening Program With Lipid Screening as a Means to Identify Familial Hyperlipidemia
Determination of FH status by genetic testing in school age children who have demonstrated elevated cholesterol on baseline screening.
- Trial name
- NCT05767996
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Poudre Valley Health System
Hyperlipoproteinemia (a)
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or…
- Trial name
- NCT07172646
- Testing
- SRSD216 injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sirius Therapeutics Co., Ltd.